Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.1 (
ERK
)
95,504
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The human insulin receptor gene,
INSR
, and its promoter region have been isolated and characterized. The gene spans greater than 120 kilobase pairs (kbp) and has 22 exons. All introns interrupt protein coding regions of the gene. The 11 exons encoding the alpha subunit of the receptor are dispersed over greater than 90 kbp, whereas the 11 exons encoding the beta subunit are located together in a region of approximately 30 kbp. Three transcriptional initiation sites have been identified and are located 276, 282, and 283 bp upstream of the translation initiation site. In addition, a 247-bp fragment from the promoter region possessing 62.6% of the maximal promoter activity has been identified. This promoter-active fragment lacks a TATA-like sequence but has two possible binding regions for the transcriptional factor
Sp1
. Comparison of the exon structure of the tyrosine kinase domain of the
INSR
with the corresponding regions of the human SRC, ROS, and
ERBB2
(
NGL
) protooncogenes indicates that the exon-intron organization of this region has not been well conserved.
...
PMID:Structure of the human insulin receptor gene and characterization of its promoter. 291 61
Sp1
, the pregnancy-specific beta 1-glycoprotein, was studied in normal and pathologic pregnancies. We developed a highly specific and sensitive double-antibody-radioimmunoassay by radioiodination of purified placental SP1. This RIA allowed the estimation of SP1 concentrations as low as 2 ng/ml. In a collective of 227 women with normal pregnancies we established the normal distribution curve in maternal plasma from the fifth week of gestation to term. The median value rose steadily from 3 microgram/ml in the 8th week to 140 microgram/ml in the 36th week when a plateau was formed. In more than 400 patients with pregnancies complicated by a variety of pathologic disorders the SP1 levels were controlled by either single assays or serial estimations throughout pregnancy and were compared with the normal distribution range. SP1 was also determined in about 200 samples of amniotic fluid gained by amniocentesis and during parturition of normal pregnant women from the 13th gestational week until term. The normal range was established up to the 20th w.o.p. The concentrations rose from below 0.2 microgram/ml in early pregnancy to 3 microgram/ml and generally amounted to approximately 1% of the respective serum value. Pathologic cases with diverse chromosomal anomalies, Rh-incompatibility, anencephaly, hydramnios and other abnormal conditions were examined. From these only twin-pregnancies with slightly elevated levels and cases with fetal trisomies with reduced SP1 concentrations showed aberrations from the normal distribution. The estimation of serum concentrations in mothers with diabetes or Rh-incompatibility were not significantly different from the normal collective. In diabetes a characteristic course of the follow-up curves was observed. Abortion in early pregnancy was frequently but not always indicated by reduced SP1 values. Threatened abortion with subsequent continuation of pregnancy exhibited SP1 values scattered within the normal range. Since the radioimmunological determination of SP1 is possible in the early stage of gestation (from week 8) it may serve as a useful tool for prediction at times when the determination of placental lactogen is not yet possible. In pregnancies with "small-for-date babies" the correlation between SP1 in maternal plasma and fetal growth retardation was reflected in a pronounced tendency to low SP1 levels. Serial determinations of SP1 in the serum of women with
EPH
-gestosis were compared with the corresponding HPL determinations and showed the equality of SP1 concerning the assessment of the placental function.
...
PMID:Radioimmunoassay of SP1 (pregnancy-specific beta1-glycoprotein) in maternal blood and in amniotic fluid normal and pathologic pregnancies. 678 88
Episomal plasmids for stable transfection of mammalian cell cultures were constructed that have a G418-resistance (neo) gene immediately downstream of a highly truncated promoter. These plasmids had a function hygromycin-resistance gene (hyg) as a selectable marker. Surprisingly, in
LTK
- cells, but not HeLa cells, stably transfected with these BK virus-based plasmids having no promoter elements adjacent to the neo gene, readthrough transcription, probably from about 1 kb upstream, gave almost as efficient expression of the neo gene as of the hyg gene with a full-length promoter immediately upstream. When the transfecting plasmids contained Epstein-Barr virus (EBV) DNA sequences for episomal maintenance and had multiple
Sp1
sites and a TATA box as the only promoter elements 5' to the neo gene, only about 3-9% of HeLa transfectants were G418 resistant (G418R). In transfections with analogous plasmids lacking these promoter elements 5' to the neo gene, no G418R colonies were seen. The establishment of the G418R phenotype probably required integration of plasmid DNA into favorable chromosomal sites and was aided by the presence of the TATA box plus
Sp1
sites as a subminimal promoter. The absence of detectable G418-resistance in most of the HeLa transfectant clones obtained with EBV-type plasmids, even at a high plasmid copy number and even when a TATA box and six
Sp1
sites were present immediately upstream of the neo gene, indicates that these elements do not suffice for appreciable gene expression in vivo and that this is a suitable model system for studying DNA rearrangements that can potentiate expression of the neo gene.
...
PMID:Reporter gene expression upon stable transfection when only a TATA box or a TATA box plus Sp1 sites are present 5' to the gene. 764 18
The beta-adrenergic receptor kinase (beta
ARK
) specifically phosphorylates the agonist-occupied forms of the beta 2-adrenergic receptor and related G protein-coupled receptors. beta
ARK
is one of the best characterized members of a growing family of G protein-coupled receptor kinases. In this article we report the isolation and structural organization of the human beta
ARK
gene. The gene spans approximately 23 kilobases and is composed of 21 exons interrupted by 20 introns. Exon sizes range from 52 bases (exon 7) to over 1200 bases (exon 21), intron sizes from 68 bases (intron L) to 10.8 kilobases (intron A). The splice sites for donor and acceptor were in agreement with the canonical GT/AG rule. Functional regions of beta
ARK
are described with respect to their location within the exon-intron organization of the gene. Primer extension and RNase protection assays suggest a major transcription start site approximately 246 bases upstream of the start ATG. Sequence analysis of the 5'-flanking/promoter region reveals many features characteristic of mammalian housekeeping genes, i.e. the lack of a TATA box, an absent or nonstandard positioned CAAT box, high GC content, and the presence of
Sp1
-binding sites. The extraordinarily high GC content of the 5'-flanking region (> 80%) helps define this region as a CpG island that may be a principal regulator of beta
ARK
expression.
...
PMID:Structure of the human gene encoding the beta-adrenergic receptor kinase. 819 24
The p53 tumor suppressor gene product, a sequence-specific DNA-binding protein, has been shown to act as a transcriptional activator and repressor both in vitro and in vivo. Consistent with its role in regulating transcription are recent observations that the N-terminal acidic domain of p53 binds directly to the TATA box-binding protein subunit of the general transcription factor, TF IID. It is now demonstrated that wild-type p53 (wt-p53) inhibits human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR)-directed chloramphenicol acetyltransferase activity in a cotransfection assay system. Importantly, this effect of wt-p53 on the HIV-1 LTR was also demonstrated by in vitro transcription assays. In addition, the
Sp1
sites and the TATA box of the HIV-1 LTR are demonstrated to be the primary sites involved with p53-induced effects on this viral promoter. The upstream elements of the HIV-1 LTR, including the nuclear factor kappa B (NF-kappa B) binding sites, decrease the p53-induced inhibitory effects on viral transcription. In the presence of the HIV-1 TAR sequence and Tat protein, the HIV-1 LTR also becomes less sensitive to wt-p53-induced inhibition. By using a retroviral vector delivery system, mutant forms of p53 genes were expressed in two HIV-1 latently infected cell lines,
ACH
-2 and U1. In the
ACH
-2 cell line, which is now demonstrated to contain an endogenous mutant form of p53 (amino acid 248, Arg to Gln), additional mutant p53 proteins did not alter HIV-1 replication. In U1 cells, which completely lack endogenous p53, overexpression of mutant p53 led to an increase in HIV-1 replication. Thus, these data indicate a possible functional role for wt-p53 and mutant p53 proteins in the control of HIV-1 replication patterns and proviral latency.
...
PMID:The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. 820 5
Analysis of the promoter for the herpes simplex virus (HSV) immediate-early (alpha) gene alpha 0 in a short-term transient expression assay revealed that a SacI-to-NcoI fragment from -786 to +148 relative to the cap site directed the synthesis of chloramphenicol acetyltransferase when the fragment was present in either orientation. Although the constitutive levels of promoter activity were similar with either orientation, the reverse-orientation promoter was not induced in response to infection with HSV. Analysis of sequences composing the putative promoter in the opposite orientation revealed the presence of important regulatory elements associated with alpha promoters. These include an alpha-trans-inducing factor (alpha-TIF)-like response element, a high-affinity ICP4-binding site, numerous
Sp1
-binding sites, and a TATA box. Sequences contained within this region formed specific DNA-protein complexes in extracts from mock-infected and HSV-infected HeLa cells. Transient expression assays revealed that this sequence was positively regulated by the alpha 0 and alpha-
TIF
genes but negatively regulated by alpha 4. Finally, nuclear run-on transcription assays revealed that this promoter is active in its correct genomic context during the course of virus infection. We suggest that the promoter is a hybrid between an alpha and beta promoter because it exhibits maximal expression at 8 h postinfection and is expressed in the presence of cycloheximide.
...
PMID:Identification of a promoter mapping within the reiterated sequences that flank the herpes simplex virus type 1 UL region. 838 Apr 59
Using a DNA transfection-tumorigenicity assay we have recently identified the
UFO
oncogene. It encodes a tyrosine kinase receptor characterized by the juxtaposition of two immunoglobulin-like and two fibronectin type III repeats in its extracellular domain. Here we describe the genomic organization of the human
UFO
locus. The UFO receptor is encoded by 20 exons that are distributed over a region of 44 kb. Different isoforms of
UFO
mRNA are generated by alternative splicing of exon 10 and differential usage of two imperfect polyadenylation sites resulting in the presence or absence of 1.5-kb 3' untranslated sequences. Primer extension and S1 nuclease analyses revealed multiple transcriptional initiation sites including a major site 169 bp upstream of the translation start site. The promoter region is GC rich, lacks TATA and CAAT boxes, but contains potential recognition sites for a variety of trans-acting factors, including
Sp1
, AP-2 and the cyclic AMP response element-binding protein. Proto-
UFO
and its oncogenic counterpart exhibit identical cDNA and promoter regions sequences. Possible modes of
UFO
activation are discussed.
...
PMID:The genomic structure of the human UFO receptor. 838 Dec 25
Isolation and characterization of genomic clones encoding human alpha-platelet derived growth factor receptor (HGMW-approved symbol
PDGFRA
) revealed that the gene spans approximately 65 kb and contains 23 exons. The 5'-untranslated region of the mRNA is encoded by exon 1, and a large intron of 23 kb separates exon 2 encoding the translation initiator codon AUG and the signal sequence. The locations of exon/intron boundaries in the extracellular immunoglobulin-like domains, the transmembrane domain, the two cytoplasmic tyrosine kinase domains, and the kinase insertion domain are very similar to those in c-kit and macrophage colony stimulating factor-1 receptor genes. The transcription start site was mapped to a position 393 bp upstream of the AUG translocation initiator codon by S1 mapping and primer extension analysis. The 5'-flanking region of the gene lacks a typical TATA box but contains a typical CCAAT box and GATA motifs. This region also contains potential sites for AP-1, AP-2, Oct-1, Oct-2, and
Sp1
. The 5'-flanking region of the gene was fused to the luciferase reporter gene, and transcription units of the gene were determined.
...
PMID:Structure, organization, and transcription units of the human alpha-platelet-derived growth factor receptor gene, PDGFRA. 858 21
The
NTRK1
gene encodes one of the receptors for the Nerve Growth Factors and it is located at 1q21-22. Rearrangements of
NTRK1
are frequently detected in human papillary thyroid carcinoma and lead to the formation of chimeric oncogenes, similarly to what observed for the other neurotrophin receptor
RET
. In addition, the two receptor genes are target of point mutations associated with different human diseases.
RET
is affected by germ line and somatic mutations in MEN2A, MEN2B tumor syndromes and in the abnormal developmental Hirschsprung disease, whereas mutations of
NTRK1
have been reported very recently in patients with congenital insensitivity to pain with anidrosis (CIPA). With the aim to provide a tool for searching mutations along the whole
NTRK1
gene, we have determined its genomic organization. Our results demonstrated that
NTRK1
is contained within 25 Kb of DNA and is organized in 17 exons, one of which is alternatively spliced. The sequence of the 5' flanking region indicates a high content in C/G, the absence of TATA box, the presence of several putative binding sites for
Sp1
, AP1, AP2, AP3, ATF and GCF transcription factors.
...
PMID:Genomic organization of the human NTRK1 gene. 895 89
The cyclin-dependent kinase inhibitor p27Kip1 plays an important role in regulating cell-cycle progression. p27Kip1 directly inhibits the catalytic activity of cyclin/cdks (cyclin-dependent kinase) complexes and/or interferes physically with cyclin/cdks activation by
CAK
. Interestingly, the expression level of p27Kip1 mRNA was maximal in resting Go T-cells and rapidly declined following anti-CD3 activation. We report here the cloning of p27Kip1 gene from murine genomic DNA and the functional analysis of the promoter of the p27Kip1 gene. The gene consists of at least three exons and spans more than 5.6 kb of DNA. Primer extension and nuclease S1 protection analysis revealed two major transcription initiation sites. The promoter region lacked a TATA box but contained potential binding sites for the transcriptional factors including two
Sp1
, CRE, Myb and NFkB located at positions -153, -178, -286, -875, and -1011, respectively. To analyze the regulatory mechanisms controlling p27Kip1 gene expression, we characterized the 5'-flanking region from nt -1609 to +178. The -326 to -615 region contained positive regulatory elements.
...
PMID:Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. 897 54
1
2
3
4
5
6
7
8
9
10
Next >>